-2025 is poised to be a catalyst-rich year with key updates across several programs- -Starting 2025 with a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and ...

-Starting 2025 with a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities- ZUG, Switzerland and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CRISPR ...

-Starting 2025 with a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities- ZUG, Switzerland and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CRISPR ...

Then we will focus into the subgroup of Bayer AG to do with pharmaceuticals ... its own name and using its own Bayer Cross corporate logo. This was under the leadership of Dr Manfred Schneider ...

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. Journavx is a first-in-class non-opioid painkiller that acts on sodium channels in the ...

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...